Answers are grounded in this paper and cite their sources.
Observational analysis identifies inflammatory markers and oxidative stress in hypertensive patients, indicating significant health risks.
Background: Subclinical hypothyroidism has emerged as a potential contributor to the metabolic dysfunction-associated steatotic liver disease, particularly in individuals with coexisting hypertension. Aims: To evaluate metabolic profiles, inflammatory markers, and oxidative stress parameters in hypertensive patients with metabolic dysfunction-associated steatotic liver disease, depending on the presence of concomitant subclinical hypothyroidism. Methods: A total of 126 patients examined from 2019 to 2022 were divided into four groups: Group 1 – controls (n = 30); Group 2 – hypertensive patients with steatotic liver disease (n = 26); Group 3 – patients with hypertension and subclinical hypothyroidism (n = 18); and Group 4 – patients with all three conditions (n = 52). In Groups 3 and 4, thyroid-stimulating hormone (TSH) levels ranged from 4 to 10 mU/L. Anthropometric parameters, biochemical profile, inflammatory (C-reactive protein, CRP, tumor necrosis factor α, TNF-α), and oxidative stress markers (total hydroperoxide content, THP, total antioxidant activity, TAA) were assessed. Results: The presence of subclinical hypothyroidism (in either Group 3 or 4) was associated with significantly higher hip circumference (p < 0.05), lower waist-to-hip ratio (p < 0.001), elevated levels of glycated hemoglobin (p < 0.05), CRP (p < 0.05), and TNF-α (p < 0.001). Significantly higher levels of non-high-density lipoprotein cholesterol (non-HDL-C) (p = 0.005) and low-density lipoprotein cholesterol (p = 0.028), total cholesterol (p = 0.021), aspartate aminotransferase (p = 0.01), alkaline phosphatase (p = 0.034), THP (p = 0.014), and lower levels of HDL-C (p = 0.027) and glomerular filtration rate (p = 0.048) were observed in Group 4 compared to Group 2. In Group 4, TSH levels were positively associated with glucose (p = 0.008), TNF-α (p < 0.001), and inversely associated with HDL-C (p < 0.001), glomerular filtration rate (p < 0.001), and TAA (p = 0.012). A significantly higher proportion had a high cardiovascular risk according to SCORE2 in Group 4 compared to Group 2 (p = 0.023). Conclusion: Subclinical hypothyroidism significantly contributes to the cardiometabolic burden in hypertensive patients with metabolic dysfunction-associated steatotic liver disease. Even among patients with mild subclinical hypothyroidism, higher systemic inflammation, oxidative stress, impaired glucose control, and lipid dysregulation are observed.
No takes yet. Share an insight, caveat, or question.
Kolesnikova et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: